Open Label Phase 1 Study in Japan for patient with advanced solid malignancies

Exclusion Criteria

• - Clinically significant abnormalities of glucose metabolism as defined by any of the following:
• -Diagnosis of diabetes mellitus type I or II (irrespective of management)
• -Baseline fasting glucose value of ≥7 mmol/l (126mg/dL)
• -Glycosylated haemoglobin (HbA1C) >6.5%
• - Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment
• - Inadequate bone marrow reserve or organ function
• - Any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or active infection
• - With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment